Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase III Trial to Evaluate the Efficacy of Asunercept for the Treatment of Hospitalized Patients With Moderate to Severe COVID 19 Disease

NCT05639192 is registered in ClinicalTrials.gov with Apogenix GmbH as lead sponsor.

NCT NCT05639192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05639192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase III Trial to Evaluate the Efficacy of Asunercept for the Treatment of Hospitalized Patients With Moderate to Severe COVID 19 Disease
Lead sponsor
Apogenix GmbH
Phase
Phase 3
Overall status
Terminated
Start date
November 3, 2022
Completion date
August 18, 2023
Enrollment
34 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19